Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Annette Schlemmer"'
Autor:
Salome Kristensen, Erik Berg Schmiddt, Annette Schlemmer, Claus Rasmussen, Esther Lindgreen, Martin Berg Johansen, Jeppe Hagstrup Christensen
Publikováno v:
Artery Research, Vol 16 (2016)
Background: Patients with psoriatic arthritis are at high cardiovascular risk. Marine n-3 polyunsaturated fatty acids (PUFA) may reduce the incidence of cardiovascular disease. The aim of this study was to investigate the effect of marine n-3 PUFA on
Externí odkaz:
https://doaj.org/article/ac3b849c28674f7881d753838008f327
Autor:
Line Uhrenholt, Robin Christensen, Wilfred K H Dinesen, Caroline H Liboriussen, Stine S Andersen, Lene Dreyer, Annette Schlemmer, Ellen-Margrethe Hauge, Conni Skrubbeltrang, Peter C Taylor, Salome Kristensen
Publikováno v:
Uhrenholt, L, Christensen, R, Dinesen, W K H, Liboriussen, C H, Andersen, S S, Dreyer, L, Schlemmer, A, Hauge, E-M, Skrubbeltrang, C, Taylor, P C & Kristensen, S 2022, ' Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis : a systematic review and meta-analysis ', Rheumatology, vol. 61, no. 8, pp. 3107-3122 . https://doi.org/10.1093/rheumatology/keab902
Uhrenholt, L, Christensen, R, Dinesen, W K H, Liboriussen, C H, Andersen, S S, Dreyer, L, Schlemmer, A, Hauge, E-M, Skrubbeltrang, C, Taylor, P C & Kristensen, S 2022, ' Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis : A systematic review and meta-analysis ', Rheumatology, vol. 61, no. 8, pp. 3107–3122 . https://doi.org/10.1093/rheumatology/keab902
Uhrenholt, L, Christensen, R, Dinesen, W K H, Liboriussen, C H, Andersen, S S, Dreyer, L, Schlemmer, A, Hauge, E-M, Skrubbeltrang, C, Taylor, P C & Kristensen, S 2022, ' Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis : A systematic review and meta-analysis ', Rheumatology, vol. 61, no. 8, pp. 3107–3122 . https://doi.org/10.1093/rheumatology/keab902
Objective To evaluate flare risk when tapering or withdrawing biologic or targeted synthetic DMARDs (bDMARDs or tsDMARDs) compared with continuation in patients with inflammatory arthritis in sustained remission or with low disease activity. Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1773c0a67e86ba7e2f9238c06b2aa062
https://pure.au.dk/portal/da/publications/risk-of-flare-after-tapering-or-withdrawal-of-biologictargeted-synthetic-diseasemodifying-antirheumatic-drugs-in-patients-with-rheumatoid-arthritis-or-axial-spondyloarthritis(69ca9bb0-bcb1-4219-9dd9-166484032d04).html
https://pure.au.dk/portal/da/publications/risk-of-flare-after-tapering-or-withdrawal-of-biologictargeted-synthetic-diseasemodifying-antirheumatic-drugs-in-patients-with-rheumatoid-arthritis-or-axial-spondyloarthritis(69ca9bb0-bcb1-4219-9dd9-166484032d04).html
Autor:
Peter C. Taylor, Lene Dreyer, Salome Kristensen, Robin Christensen, Mikkel Kramme Abildtoft, Annette Schlemmer, Line Uhrenholt, Niels Steen Krogh, Ellen Margrethe Hauge
Publikováno v:
Uhrenholt, L, Christensen, R, Dreyer, L, Schlemmer, A, Hauge, E M, Krogh, N S, Abildtoft, M K, Taylor, P C & Kristensen, S 2022, ' Using a novel smartphone application for capturing of patient-reported outcome measures among patients with inflammatory arthritis:A randomized, crossover, agreement study ', Scandinavian Journal of Rheumatology, vol. 51, no. 1, pp. 25-33 . https://doi.org/10.1080/03009742.2021.1907925
Uhrenholt, L, Christensen, R, Dreyer, L, Schlemmer, A, Hauge, E-M, Krogh, N S, Abildtoft, M K, Taylor, P C & Kristensen, S 2022, ' Using a novel smartphone application for capturing of patient-reported outcome measures among patients with inflammatory arthritis: A randomized, crossover, agreement study ', Scandinavian Journal of Rheumatology, vol. 51, no. 1, pp. 25-33 . https://doi.org/10.1080/03009742.2021.1907925
Uhrenholt, L, Christensen, R, Dreyer, L, Schlemmer, A, Hauge, E-M, Krogh, NS, Abildtoft, MK, Taylor, PC & Kristensen, S 2022, ' Using a novel smartphone application for capturing of patient-reported outcome measures among patients with inflammatory arthritis:A randomized, crossover, agreement study ', Scandinavian Journal of Rheumatology, vol. 51, no. 1, pp. 25-33 . https://doi.org/10.1080/03009742.2021.1907925
Uhrenholt, L, Christensen, R, Dreyer, L, Schlemmer, A, Hauge, E-M, Krogh, N S, Abildtoft, M K, Taylor, P C & Kristensen, S 2022, ' Using a novel smartphone application for capturing of patient-reported outcome measures among patients with inflammatory arthritis: A randomized, crossover, agreement study ', Scandinavian Journal of Rheumatology, vol. 51, no. 1, pp. 25-33 . https://doi.org/10.1080/03009742.2021.1907925
Uhrenholt, L, Christensen, R, Dreyer, L, Schlemmer, A, Hauge, E-M, Krogh, NS, Abildtoft, MK, Taylor, PC & Kristensen, S 2022, ' Using a novel smartphone application for capturing of patient-reported outcome measures among patients with inflammatory arthritis:A randomized, crossover, agreement study ', Scandinavian Journal of Rheumatology, vol. 51, no. 1, pp. 25-33 . https://doi.org/10.1080/03009742.2021.1907925
Objectives: In Denmark, patients with inflammatory arthritis (IA) have completed patient-reported outcome measures (PROMs) via touchscreens in the outpatient clinic since 2006. However, current technology makes it possible for patients to use their o
Autor:
Morten A. Karsdal, Signe Holm Nielsen, Samra Sardar, Annette Schlemmer, Jeppe Hagstrup Christensen, Salome Kristensen, Erik Berg Schmidt, Anne-Christine Bay-Jensen, Anne Sofie Siebuhr
Publikováno v:
Holm Nielsen, S, Sardar, S, Siebuhr, A S, Schlemmer, A, Schmidt, E B, Bay-Jensen, A C, Karsdal, M A, Christensen, J H & Kristensen, S 2021, ' Effect of n-3 PUFA on extracellular matrix protein turnover in patients with psoriatic arthritis : a randomized, double-blind, placebo-controlled trial ', Rheumatology International, vol. 41, no. 6, pp. 1065-1077 . https://doi.org/10.1007/s00296-021-04861-z
Rheumatology International
Nielsen, S H, Sardar, S, Siebuhr, A S, Schlemmer, A, Schmidt, E B, Bay-Jensen, A-C, Karsdal, M A, Christensen, J H & Kristensen, S 2021, ' Effect of n-3 PUFA on extracellular matrix protein turnover in patients with psoriatic arthritis: a randomized, double-blind, placebo-controlled trial ', Rheumatology International, vol. 41, no. 6, pp. 1065-1077 . https://doi.org/10.1007/s00296-021-04861-z
Rheumatology International
Nielsen, S H, Sardar, S, Siebuhr, A S, Schlemmer, A, Schmidt, E B, Bay-Jensen, A-C, Karsdal, M A, Christensen, J H & Kristensen, S 2021, ' Effect of n-3 PUFA on extracellular matrix protein turnover in patients with psoriatic arthritis: a randomized, double-blind, placebo-controlled trial ', Rheumatology International, vol. 41, no. 6, pp. 1065-1077 . https://doi.org/10.1007/s00296-021-04861-z
Psoriatic arthritis (PsA) is a chronic inflammatory disease characterized by involvement of skin, axial and peripheral skeleton. An altered balance between extracellular matrix (ECM) formation and breakdown is a key event in PsA, and changes in ECM p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa0599f4696f253e56568ea9e6e6b8eb
https://vbn.aau.dk/da/publications/e9edbb0d-6415-4945-a1d9-e42b8b53ac0b
https://vbn.aau.dk/da/publications/e9edbb0d-6415-4945-a1d9-e42b8b53ac0b
Autor:
J. Hagstrup Christensen, Dovile Sinkeviciute, M.A. Karsdal, S Holm Nielsen, E. Berg Schmidt, Søren Risom Kristensen, Annette Schlemmer, Anne-Christine Bay-Jensen
Publikováno v:
Annals of the Rheumatic Diseases. 79:1912-1913
Background:Psoriatic Arthritis (PsA) is a chronic inflammatory disease, characterized by involvement of skin, axial and peripheral skeleton. Prolargin is a class II small leucine-rich proteoglycan found to be expressed in connective tissues of patien
Autor:
Robin Christensen, Annette Schlemmer, Ellen-Margrethe Hauge, Line Uhrenholt, Salome Kristensen, Lene Dreyer, Maria E. Suarez-Almazor
Publikováno v:
BMJ Open
Uhrenholt, L, Schlemmer, A, Hauge, E-M, Christensen, R, Dreyer, L, Suarez-Almazor, M E & Kristensen, S 2019, ' Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis : protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial) ', BMJ Open, vol. 9, no. 7, e028517, pp. 1-11 . https://doi.org/10.1136/bmjopen-2018-028517
Uhrenholt, L, Schlemmer, A, Hauge, E M, Christensen, R, Dreyer, L, Suarez-Almazor, M E & Kristensen, S 2019, ' Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis : Protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial) ', BMJ Open, vol. 9, no. 7, e028517 . https://doi.org/10.1136/bmjopen-2018-028517
Uhrenholt, L, Schlemmer, A, Hauge, E-M, Christensen, R, Dreyer, L, Suarez-Almazor, M E & Kristensen, S 2019, ' Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis : protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial) ', BMJ Open, vol. 9, no. 7, e028517 . https://doi.org/10.1136/bmjopen-2018-028517
Uhrenholt, L, Schlemmer, A, Hauge, E-M, Christensen, R, Dreyer, L, Suarez-Almazor, M E & Kristensen, S 2019, ' Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis : protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial) ', BMJ Open, vol. 9, no. 7, e028517, pp. 1-11 . https://doi.org/10.1136/bmjopen-2018-028517
Uhrenholt, L, Schlemmer, A, Hauge, E M, Christensen, R, Dreyer, L, Suarez-Almazor, M E & Kristensen, S 2019, ' Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis : Protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial) ', BMJ Open, vol. 9, no. 7, e028517 . https://doi.org/10.1136/bmjopen-2018-028517
Uhrenholt, L, Schlemmer, A, Hauge, E-M, Christensen, R, Dreyer, L, Suarez-Almazor, M E & Kristensen, S 2019, ' Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis : protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial) ', BMJ Open, vol. 9, no. 7, e028517 . https://doi.org/10.1136/bmjopen-2018-028517
IntroductionThe The BIOlogical Dose OPTimisation (BIODOPT) trial is a pragmatic, multicentre, randomised controlled, open-label, parallel-group, equivalence study designed to evaluate tapering of biological disease-modifying antirheumatic drugs (bDMA
Autor:
Lene Dreyer, Niels Steen Krogh, R. Pelck, Laura Danielsen, Inger Marie Jensen Hansen, D. G. A. Kraus, Oliver Hendricks, L.S. Andersen, Henrik Nordin, Inge Juul Sørensen, Jakob Espesen, J. K. Pedersen, Bente Glintborg, S. R. Christensen, Marcin Ryszard Kowalski, Lone Salomonsen, Annette Schlemmer, Mikkel Østergaard, Merete Lund Hetland, N. al Chaer, Johnny Lillelund Raun, A.A. Mohamoud, Anne Gitte Loft
Publikováno v:
Scandinavian Journal of Rheumatology. 45:1-52
Autor:
Gerdur Grondal, Hanne Merete Lindegaard, Annette Schlemmer, Lars Juul, B. Agular, Inger Marie Jensen Hansen, Erik Jensen, P. Johansen
Publikováno v:
Lindegaard, H M, Johansen, P, Gröndal, G, Jensen, E C, Juul, L, Schlemmer, A M, Agular, B & Hansen, I 2016, ' Doubling the single-dose infusion rate of tocilizumab in rheumatoid arthritis is safe and efficacious ', Scandinavian Journal of Rheumatology, vol. 45, no. 5, pp. 262-266 . https://doi.org/10.3109/03009742.2015.1112030
Lindegaard, H M, Johansen, P, Gröndal, G, Jensen, E C, Juul, L, Schlemmer, A M, Agular, B & Jensen Hansen, I M 2016, ' Doubling the single-dose infusion rate of tocilizumab in rheumatoid arthritis is safe and efficacious ', Scandinavian Journal of Rheumatology, vol. 45, no. 4, pp. 262-266 . https://doi.org/10.3109/03009742.2015.1112030
Lindegaard, H M, Johansen, P, Gröndal, G, Jensen, E C, Juul, L, Schlemmer, A M, Agular, B & Jensen Hansen, I M 2016, ' Doubling the single-dose infusion rate of tocilizumab in rheumatoid arthritis is safe and efficacious ', Scandinavian Journal of Rheumatology, vol. 45, no. 4, pp. 262-266 . https://doi.org/10.3109/03009742.2015.1112030
OBJECTIVES: To investigate the impact of enhanced infusion rate of tocilizumab on the occurrence of infusion reactions, overall safety, and efficacy in rheumatoid arthritis (RA).METHOD: We conducted a 24-week multicentre, open-label, randomized paral
Autor:
Kristian Stengaard-Pedersen, Torkell Ellingsen, Hanne Merete Lindegaard, Peter Junker, Anette Jørgensen, Julia S. Johansen, Lykke Midtbøll Ørnbjerg, Tine Lottenburger, Rebecca Bolce, Cecilie Heegaard Brahe, Asta Linauskas, X Wang, Nadine Defranoux, Eric H. Sasso, Palle Ahlquist, Johnny Lillelund Raun, Mikkel Østergaard, Sophine B. Krintel, Ib Hansen, Christian Gytz Ammitzbøll, Kim Hørslev-Petersen, Annette Schlemmer, Merete Lund Hetland, Mette Yde Dam
Publikováno v:
Brahe, C H, Østergaard, M, Johansen, J S, Defranoux, N, Wang, X, Bolce, R, Sasso, E, Ørnbjerg, L, Hørslev-Petersen, K, Stengaard-Pedersen, K, Junker, P, Ellingsen, T, Ahlquist, P, Lindegaard, H, Linauskas, A, Schlemmer, A, Dam, M Y, Hansen, I, Lottenburger, T, Ammitzbøll, C, Jørgensen, A, Krintel, S, Raun, J & Hetland, M 2019, ' Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis : a post-hoc study of the OPERA trial ', Scandinavian Journal of Rheumatology, vol. 48, no. 1, pp. 9-16 . https://doi.org/10.1080/03009742.2018.1464206
Brahe, C H, Østergaard, M, Johansen, J S, Defranoux, N, Wang, X, Bolce, R, Sasso, E H, Ørnbjerg, L M, Hørslev-Petersen, K, Stengaard-Pedersen, K, Junker, P, Ellingsen, T, Ahlquist, P, Lindegaard, H, Linauskas, A, Schlemmer, A, Dam, M Y, Hansen, I, Lottenburger, T, Ammitzbøll, C, Jørgensen, A, Krintel, S B, Raun, J & Hetland, M L 2019, ' Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis : a post-hoc study of the OPERA trial ', Scandinavian Journal of Rheumatology, vol. 48, no. 1, pp. 9-16 . https://doi.org/10.1080/03009742.2018.1464206
Brahe, C H, Østergaard, M, Johansen, J S, Defranoux, N, Wang, X, Bolce, R, Sasso, E H, Ørnbjerg, L M, Hørslev-Petersen, K, Stengaard-Pedersen, K, Junker, P, Ellingsen, T, Ahlquist, P, Lindegaard, H, Linauskas, A, Schlemmer, A, Dam, M Y, Hansen, I, Lottenburger, T, Ammitzbøll, C, Jørgensen, A, Krintel, S B, Raun, J & Hetland, M L 2019, ' Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis : a post-hoc study of the OPERA trial ', Scandinavian Journal of Rheumatology, vol. 48, no. 1, pp. 9-16 . https://doi.org/10.1080/03009742.2018.1464206
OBJECTIVES: Measurement of serum biomarkers at disease onset may improve prediction of disease course in patients with early rheumatoid arthritis (RA). We evaluated the multi-biomarker disease activity (MBDA) score and early changes in MBDA score for
Autor:
B. Glintborg, Abdiweli Awil Mohamoud, Mikkel Østergaard, D. G. A. Kraus, Laura Danielsen, Johnny Lillelund Raun, Niels Steen Krogh, Marcin Ryszard Kowalski, Inger Marie Jensen Hansen, Jens Kristian Pedersen, Lene Dreyer, Oliver Hendricks, Henrik Nordin, Anne Gitte Loft, R. Pelck, Jakob Esbesen, Nabil Al Chaer, Inge Juul Sørensen, Merete Lund Hetland, Annette Schlemmer, S. R. Christensen, Lone Salomonsen, Lis Smedegaard Andersen
Publikováno v:
Glintborg, B, Sørensen, I J, Østergaard, M, Dreyer, L, Mohamoud, A A, Krogh, N S, Hendricks, O, Andersen, L S, Raun, J L, Kowalski, M R, Danielsen, L, Pelck, R, Nordin, H, Pedersen, J K, Kraus, D, Christensen, S R, Hansen, I M, Esbesen, J, Schlemmer, A, Loft, A G, Al Chaer, N, Salomonsen, L & Hetland, M L 2017, ' Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis : Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry ', Journal of Rheumatology, vol. 44, no. 1, pp. 59-69 . https://doi.org/10.3899/jrheum.160958
Glintborg, B, Sørensen, I J, Østergaard, M, Dreyer, L, Mohamoud, A A, Krogh, N S, Hendricks, O, Andersen, L S, Raun, J L, Kowalski, M R, Danielsen, L, Pelck, R, Nordin, H, Pedersen, J K, Kraus, D G A, Christensen, S R, Hansen, I M J, Esbesen, J, Schlemmer, A, Loft, A G, Al Chaer, N, Salomonsen, L & Hetland, M L 2017, ' Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis : Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry ', Journal of Rheumatology, vol. 44, no. 1, pp. 59-69 . https://doi.org/10.3899/jrheum.160958
Glintborg, B, Sørensen, I J, Østergaard, M, Dreyer, L, Mohamoud, A A, Krogh, N S, Hendricks, O, Andersen, L S, Raun, J L, Kowalski, M R, Danielsen, L, Pelck, R, Nordin, H, Pedersen, J K, Kraus, D G A, Christensen, S R, Jensen Hansen, I M, Esbesen, J, Schlemmer, A, Loft, A G, Al Chaer, N, Salomonsen, L & Hetland, M L 2017, ' Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis : Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry ', Journal of Rheumatology, vol. 44, no. 1, pp. 59-69 . https://doi.org/10.3899/jrheum.160958
Glintborg, B, Sørensen, I J, Østergaard, M, Dreyer, L, Mohamoud, A A, Krogh, N S, Hendricks, O, Andersen, L S, Raun, J L, Kowalski, M R, Danielsen, L, Pelck, R, Nordin, H, Pedersen, J K, Kraus, D G A, Christensen, S R, Hansen, I M J, Esbesen, J, Schlemmer, A, Loft, A G, Al Chaer, N, Salomonsen, L & Hetland, M L 2017, ' Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis : Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry ', Journal of Rheumatology, vol. 44, no. 1, pp. 59-69 . https://doi.org/10.3899/jrheum.160958
Glintborg, B, Sørensen, I J, Østergaard, M, Dreyer, L, Mohamoud, A A, Krogh, N S, Hendricks, O, Andersen, L S, Raun, J L, Kowalski, M R, Danielsen, L, Pelck, R, Nordin, H, Pedersen, J K, Kraus, D G A, Christensen, S R, Jensen Hansen, I M, Esbesen, J, Schlemmer, A, Loft, A G, Al Chaer, N, Salomonsen, L & Hetland, M L 2017, ' Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis : Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry ', Journal of Rheumatology, vol. 44, no. 1, pp. 59-69 . https://doi.org/10.3899/jrheum.160958
Objective.To compare baseline disease activity and treatment effectiveness in biologic-naive patients with nonradiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) who initiate tumor necrosis factor inhibitor (TNFi) treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cd77a674a776528ab55f6cdfa54f0c0
https://pure.au.dk/portal/da/publications/ankylosing-spondylitis-versus-nonradiographic-axial-spondyloarthritis(a4ec44b6-168b-422f-9d65-af16decdb758).html
https://pure.au.dk/portal/da/publications/ankylosing-spondylitis-versus-nonradiographic-axial-spondyloarthritis(a4ec44b6-168b-422f-9d65-af16decdb758).html